(NASDAQ: MGNX) Macrogenics's forecast annual revenue growth rate of -8.07% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Macrogenics's revenue in 2026 is $157,082,000.On average, 8 Wall Street analysts forecast MGNX's revenue for 2026 to be $8,927,440,625, with the lowest MGNX revenue forecast at $3,675,219,772, and the highest MGNX revenue forecast at $14,549,598,855. On average, 6 Wall Street analysts forecast MGNX's revenue for 2027 to be $5,314,830,530, with the lowest MGNX revenue forecast at $373,751,163, and the highest MGNX revenue forecast at $10,111,621,607.
In 2028, MGNX is forecast to generate $9,031,684,147 in revenue, with the lowest revenue forecast at $4,547,305,819 and the highest revenue forecast at $14,562,947,111.